1. Generics Bulletin
  2. >>Business

Adalvo Partners With AmbioPharm For Several Complex Products

Development And Licensing Partnership Includes ‘Difficult-To-Make’ Peptide Products

 
• By Akriti Seth

Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.

Strategic_Partnership
Adalvo and AmbioPharm have partnered on a basket of difficult-to-make peptides with a potential market of $3bn • Source: Shutterstock

Alvogen’s new B2B sister company has announced entering into partnership with US-based AmbioPharm to co-develop, license and commercialize several complex pharmaceutical products in key global markets.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business